Transition from First Drug Use to Regular Injection among People Who Inject Drugs in Iran

Masoomeh Koozegar1, Armita Shahesmaeili MD, PhD2, Mehdi Noroozi PhD3

Abstract

Background: The study aimed to evaluate the interval between first drug use and regular injection and factors associated with transition from first injection into premature regular injection among people who inject drugs (PWIDs).

Methods: In a multicenter cross-sectional study, we recruited 400 PWIDs using snowball sampling. Age of first drug use, age of initiation of regular injection, and demographic and behavioral data were collected using face to face interview. Premature transition to regular injection was defined as initiation of regular injection within the five years of first injection. Data were analyzed using bivariate and multivariate logistic regression survey analysis.

Findings: The mean age of first drug use and age of initiation of regular injection was 29.87 ± 6.54 years, respectively. Having history of sexual abuse in childhood [adjusted odds ratio (AOR) = 3.1], history of imprisonment (AOR = 3.4), use of heroin as the first drug (AOR = 4.3), and doing the first injection at friends’ houses (AOR = 2.2) or in ruins (AOR = 2.2) significantly increased the chance of premature transition to regular injection, while being a female decreased the chance of premature transition to regular injection (AOR = 0.4). Compared to curiosity, being friend with a drug user (AOR = 0.4), having withdrawal symptoms (AOR = 0.2), and low cost of injection (AOR = 0.3) at the first occasion of drug injection reduced the chance of premature transition to regular injection.

Conclusion: New interventions to prevent injection initiation among drug users are needed and should be integrated in harm reduction programs.

Keywords: Intravenous substance abuse; Premature; Iran; Risk factors

Citation: Koozegar M, Shahesmaeili A, Noroozi M. Transition from First Drug Use to Regular Injection among People Who Inject Drugs in Iran. Addict Health 2018; 10(1): 32-40.

Received: 13.09.2017 Accepted: 19.11.2017
### Introduction

People who inject drugs (PWIDs) are one of the key groups at higher risk of HIV/HCV infection in some parts of the world including Iran. It is estimated that there are 12 million PWIDs around the world. According to national estimates, there are currently 208000 PWIDs in Iran, about 193000 men and 16000 women. Behaviors such as needle/syringe sharing and unsafe sex are the main factors that increase the risk of HIV/HCV in this population. Injecting drug use is the second route of HIV transmission in the world, but the first route in Iran. Around 62% of HIV infected people in Iran have the history of using injecting drugs. Low level of access to sterile syringes, lack of awareness, low perceived risk, fear of being arrested by the police because of carrying a syringe, high level of stigma, poor economic condition and support from their social network increase the risk of needle sharing and consequently human immunodeficiency virus/Hepatitis C virus (HIV/HCV) infection among PWIDs. In addition, PWIDs are at higher risk of getting tuberculosis (TB), soft tissue infections, bacteremia, botulism, cellulitis and endocarditis, overdose, fungal infections, bleeding, erythema, necrosis, thromboembolism, pain, and loss of organs compared to general population.

One of the factors that increase the likelihood of exposure to high-risk behaviors in PWIDs is the interval between the initiation of illicit drug use and the onset of drug injection and consequently becoming a regular drug injector. Shorter interval is accompanied with longer duration of exposure to high risk behaviors. This intervals may be somehow affected by several factors including demographic characteristics, social factors (such as the history of drug injection in family members, family violence, and so on), supportive mechanisms (access to addiction treatment in the beginning of injection, access to financial resources), the conditions and personal feelings in the first experience of drug use. Therefore, identification of factors associated with premature injection can play an important role in planning harm reduction programs. Thus, the aim of this study is to find the mean interval between the onset of drug use and regular injection and factors associated with premature injection.

### Methods

This cross-sectional multicenter study was conducted on 400 PWIDs who recruited from January to June 2017 in the cities of Kerman and Shiraz, Iran. A formative assessment was conducted by face to face interview with experts and key informants to identify potential sites that PWIDs live, hangout, or bargain drug in Kerman and Shiraz. Then we selected five seeds, who were people with large social network and good communication skills from different areas of each city. The study samples were recruited using snowball sampling method. Eligible participants were individuals between 18 to 45 years old who reported at least one occasion of drug injection over the past year and consented to participate in the study.

We collected the data using a questionnaire. After extensive search by search engines including Google Scholar, ScienceDirect, and PubMed the basic questionnaire was designed which contained nine sections and 100 questions. To validate the questionnaire, 15 experts including experienced epidemiologists, infectious disease specialists, psychologists, and drug use specialists reviewed each question. To check the face validity, experts were asked to investigate the questions regarding grammar, the use of proper words, the placement of items in their proper place, and the ambiguities in the questionnaire. Accordingly, two questions were deleted and other questions were revised.

The content validity was ased using quantitative method. Content validity was assessed using item and scale content validity index (I-CVI and S-CVI) and content validity ratio (CVR). All experts reviewed the questionnaire for simplicity, relevance, and clarity using a four point Likert scale (i.e., ranging from not relevant/unclear/not simple to completely relevant/clear/simple). The I-CVI was calculated as the fraction of experts rating an item by 3 or 4. The CVR was calculated using Lawshe’s approach CVR. The acceptable cut point for CVI and CVR were 0.78 and 0.49, respectively. Cronbach's alpha test was used to assess the internal consistency. The questionnaire was pilot tested on five PWIDs.

The final questionnaire consisted of nine sections and 98 questions. The first part consisted of 12 questions on general and demographic...
characteristics; the second part consisted of 24 questions on the detailed history of drug use; the third part contained eight questions on sexual behavior; the fourth section included four questions on the family history of drug use; the fifth section included nine questions on access to care and services; the sixth section consisted of six questions on the history of imprisonment; the seventh section contained seven questions on the history of violence; the eighth section included 15 questions on the history of childhood maltreatment; and the final section consisted of 13 questions on the knowledge of HIV transmission.

All information was collected using face to face interview. Four trained interviewers (two interviewers in each city) conducted all the interviews. The length of each interview was approximately 45 minutes. Each participant was given 50000 Rials incentive for participation in the study.

Regular injection was defined as injection at least once a month for one year continuously. The time to regular injection was created by subtracting the age of first injection from the age of becoming a regular injector. If the interval was less than 5 years, it was considered as premature transition to regular injection.

Data were analyzed using Stata software (version 15). As we recruited the study sample from two different cities, interclass correlation was probable. To tackle with, we analyzed data using survey analysis. The related weights were applied based on the estimated number of PWIDs in each city. Data were presented as relative frequencies and percentage for categorical as well as mean and standard deviation (SD) for continuous variables. Multivariable logistic regression was applied to determine factors associated with transition into premature regular injection adjusted for potential confounders. Variables with a P-value of less than 0.2 in univariable analysis were entered into the multivariable model. The final model was created based on the backward elimination method. The Akaike information criterion (AIC) and Bayesian information criterion (BIC) indices were calculated to select the final model. The P-value less than 0.05 was considered as significant.

The study protocol was approved by the Kerman University of Medical Sciences, Kerman, Iran, and the Ethics Committee (IR.KMU.AH.IEC.1396.108). All questionnaires were completed anonymously in a private setting.

### Results

The average age of the participants was 36.69 ± 6.07 years. The age ranged between 19 to 45 years old. The majority of participants were men (304, 76.00%), employed (207, 51.75%), and lived in the city (328, 82.00%). Most participants (159, 39.75%) were educated up to primary school, and majority of them got divorced (222, 55.50%). About 26.25% of PWIDs had no monthly income, and only 42 participants (10.50%) had income between 1o million and 20 million Rials. Most of the participants (197, 49.25%) lived lonely. Around 25% of participants lived in shelters, 27.50% were homeless, and 48% lived in their own house (Table 1).

| Variable                          | n (%)  |
|----------------------------------|--------|
| Gender                           |        |
| Female                           | 96 (24.00) |
| Male                             | 304 (76.00) |
| Age (year)                       |        |
| 18-25                            | 14 (3.50)  |
| 25-35                            | 148 (37.00)  |
| 35-45                            | 238 (59.50)  |
| Marital status                   |        |
| Single                           | 96 (24.00)  |
| Married                          | 82 (20.50)   |
| Widowed/divorced                 | 222 (55.50)  |
| Job                              |        |
| Employed                         | 207 (51.75)  |
| Unemployed                       | 164 (41.00)  |
| Illegal jobs                     | 29 (7.25)    |
| Income level                     |        |
| No income                        | 105 (26.25)  |
| Less than 5000000 Rials          | 153 (38.25)  |
| 50000000–10000000 Rials          | 100 (25.00)  |
| 100000000–20000000 Rials         | 42 (10.50)   |
| Place of birth                   |        |
| City                             | 328 (82.00)  |
| Village                          | 72 (18.00)    |
| Place of residence               |        |
| Personal house                   | 191 (47.75)  |
| Shelter                          | 99 (24.75)    |
| Homeless                         | 110 (27.50)  |
| Level of education               |        |
| Reading and writing/primary      | 159 (39.75)  |
| Middle school                    | 152 (38.00)  |
| High school/diploma              | 89 (22.25)    |
| Living with                      |        |
| Spouse/sex partner               | 64 (16.00)    |
| Parents/relatives/friends        | 139 (34.75)  |
| Lonely                           | 197 (49.25)  |

Table 1. Demographic characteristics of People who inject drugs (PWIDs) (n = 400)
The mean age of first use was 18.32 ± 4.88 years. The mean age of initiation of regular drug use was 21.38 ± 5.05 years. The mean interval between the first drug use and the first injection was 6.99 ± 4.59 years. Totally, 172 (43.00%) participants started their first injection within the five years from their first drug use, while in 228 (57.00%) participants the interval between the first drug use and first injection was more than 5 years. The most common drug used in the first experience was alcohol (54.75%) followed by opium (23.75%). The most common drug used in first injection was heroin (Table 2).

Factor associated with transition from first injection to regular injection: The mean age of first injection and the onset of regular injection was 25.32 ± 5.18 and 29.87 ± 6.54 years, respectively (Table 2). The mean interval between the onset of the first injection and initiation of regular injection was 4.52 ± 3.24 years. Approximately, 38% of PWIDs started regular injection in less than 5 years from their first injection (premature regular injection) (Table 2).

The results of multivariate analysis showed that being a female significantly decreased the chance of premature transition to regular injection [adjusted odds ratio (AOR) = 0.4, 95% confidence interval (CI): 0.2-0.8]. Compared to curiosity, being friend with a drug user (AOR = 0.4, 95% CI: 0.2-0.9), having withdrawal symptoms (AOR = 0.2, 95% CI: 0.1-0.5), and low cost of injection (AOR = 0.3, 95% CI: 0.1-0.7) at the first occasion of drug injection reduced the chance of premature transition to regular injection. In contrast, having history of sexual abuse in childhood (AOR = 3.1, 95% CI: 1.4-6.7) and history of imprisonment (AOR = 3.4, 95% CI:1.3-8.6) increased the chance of premature transition to regular injection. Furthermore, use of heroin (compared to opium) as the first drug (AOR = 4.2, 95% CI: 1.7-10.7) and doing the first injection at friends’ houses (AOR = 2.2, 95% CI: 1.1-4.6) or in ruins (AOR = 2.2, 95% CI: 1.0-4.8) significantly increased the chance of premature transition to regular injection compared to their own house (Table 3).

Table 2. Drug use behavior among people who inject drugs (PWIDs) (n = 400)

| Types of behavior                              | Value       |
|------------------------------------------------|-------------|
| Age of first drug use (mean ± SD)              | 18.32 ± 4.89|
| Age of initiation of regular drug use (mean ± SD) | 21.38 ± 5.06|
| Age of first injection (mean ± SD)             | 25.32 ± 5.19|
| Age of initiation of regular injection (mean ± SD) | 29.87 ± 6.54|
| Interval between first drug use and regular use (mean ± SD) | 3.08 ± 3.39|
| Interval between first drug use and first injection (mean ± SD) | 6.99 ± 4.59|
| Interval between first injection and regular injection (mean ± SD) | 4.52 ± 3.24|
| The types of first drug used [n (%)]           |             |
| Alcohol                                        | 219 (54.75) |
| Cigarette                                      | 150 (37.50) |
| Opium                                          | 95 (23.75)  |
| Cannabis                                       | 77 (19.25)  |
| The types of first drug injected [n (%)]       |             |
| Heroin                                         | 314 (95.73) |
| Opium                                          | 6 (1.84)    |
| Methamphetamine                                | 12 (3.70)   |
| Current drug use [n (%)]                       |             |
| Heroin                                         | 381 (95.49) |
| Methamphetamine                                | 349 (87.47) |
| Cigarette                                      | 150 (37.50) |
| Methadone                                      | 136 (34.09) |
| Cannabis                                       | 77 (19.30)  |
| Opium                                          | 69 (17.29)  |

SD: Standard deviation
### Table 3. Factors associated with transition from first injection to premature regular injection among people who inject drugs (PWIDs)

| Variable                                      | Premature transition (n = 151) | Non-premature transition (n = 249) | Crude OR (95% CI) P | Adjusted OR (95% CI) P |
|-----------------------------------------------|--------------------------------|------------------------------------|---------------------|-----------------------|
| Gender                                        |                                |                                    |                     |                       |
| Female                                        | 57 (14.20)                     | 39 (9.70)                          | 0.1 (0.1–0.4)       | < 0.001               |
| Male                                          | 94 (23.50)                     | 210 (52.50)                       | 1                   | 1                     |
| Reason of first injection                     |                                |                                    |                     |                       |
| Curiosity                                     | 23 (5.75)                      | 19 (4.70)                          | 1                   | 1                     |
| Friendship with a drug user                   | 31 (7.55)                      | 60 (15.00)                         | 0.4 (0.2–0.9)       | 0.031                 |
| Inevitably                                    | 23 (5.75)                      | 30 (7.50)                          | 0.6 (0.2–1.3)       | 0.213                 |
| Having withdrawal symptoms                    | 51 (12.75)                     | 79 (19.70)                         | 0.5 (0.2–1.0)       | 0.055                 |
| Lower cost of injection                       | 23 (5.75)                      | 61 (15.20)                         | 0.3 (0.1–0.6)       | 0.003                 |
| Childhood physical neglect                    |                                |                                    |                     |                       |
| None or minimal                               | 61 (15.25)                     | 190 (47.50)                        | 0.7 (0.4–1.2)       | 0.256                 |
| Low to moderate                               | 38 (9.50)                      | 26 (6.50)                          | 0.9 (0.5–1.6)       | 0.100                 |
| Moderate to severe                            | 12 (3.00)                      | 29 (7.25)                          | 1.0 (0.5–2.0)       | 0.804                 |
| Severe to extreme                             | 40 (10.00)                     | 4 (1.00)                           | 1.4 (0.8–2.6)       | 0.234                 |
| Childhood sexual abuse                        |                                |                                    |                     |                       |
| None or minimal                               | 83 (20.70)                     | 190 (47.50)                        | 1                   | 1                     |
| Low to moderate                               | 40 (10.00)                     | 26 (6.50)                          | 3.4 (1.9–6.0)       | < 0.001               |
| Moderate to severe                            | 21 (5.20)                      | 29 (7.20)                          | 1.6 (0.9–3.1)       | 0.110                 |
| Severe to extreme                             | 7 (1.70)                       | 4 (1.00)                           | 4.1 (1.2–14.6)      | 0.020                 |
| Age of first drug use                         |                                |                                    |                     |                       |
| ≤ 15 years                                    | 30 (7.50)                      | 79 (19.70)                         | 1                   | 1                     |
| > 15 years                                    | 121 (30.20)                    | 170 (42.50)                        | 2.3 (1.4–3.8)       | 0.001                 |
| Reason of first drug use                      |                                |                                    |                     |                       |
| Curiosity                                     | 23 (5.90)                      | 66 (17.10)                         | 1                   | 1                     |
| Friendship with addicted person               | 41 (10.60)                     | 84 (21.80)                         | 1.2 (0.6–2.3)       | 0.530                 |
| More joy                                      | 30 (7.80)                      | 33 (8.70)                          | 2.5 (1.2–5.2)       | 0.012                 |
| To forget the problems                        | 41 (10.60)                     | 41 (10.60)                         | 2.8 (1.4–5.5)       | 0.002                 |
| Other reasons                                 | 11 (2.90)                      | 15 (3.90)                          | 2.1 (0.8–5.5)       | 0.114                 |
| Place of first injection                      |                                |                                    |                     |                       |
| Own house                                      | 33 (8.20)                      | 59 (14.70)                         | 1                   | 1                     |
| Friend’s house                                | 54 (13.50)                     | 72 (18.00)                         | 1.3 (0.7–2.1)       | 0.163                 |
| Run                                           | 46 (11.50)                     | 79 (19.70)                         | 1.0 (0.6–1.9)       | 0.290                 |
| Prison                                        | 4 (1.00)                       | 12 (3.00)                          | 0.6 (0.2–2.0)       | 0.445                 |
| Park/Street                                   | 14 (3.50)                      | 27 (6.70)                          | 0.8 (0.3–1.7)       | 0.693                 |
| Types of first drug used                      |                                |                                    |                     |                       |
| Opium                                         | 28 (7.00)                      | 52 (13.00)                         | 1                   | 1                     |
| Alcohol                                       | 82 (20.50)                     | 137 (34.20)                        | 1.1 (0.5–1.5)       | 0.620                 |
| Heroin                                        | 15 (3.70)                      | 14 (3.50)                          | 2.6 (1.0–5.2)       | 0.040                 |
| Cannabis                                      | 9 (2.20)                       | 22 (5.50)                          | 0.5 (0.2–1.1)       | 0.100                 |
| Others drugs                                  | 17 (4.20)                      | 24 (6.00)                          | 1.5 (0.6–2.6)       | 0.490                 |
| History of arrest/imprisonment                |                                |                                    |                     |                       |
| No                                            | 28 (7.00)                      | 20 (5.00)                          | -                   | > 0.999               |
| Yes                                           | 123 (30.70)                    | 229 (57.20)                        | 0.34 (1.2–2.9)      | < 0.001               |
| Sex relationship                              |                                |                                    |                     |                       |
| Yes                                           | 138 (34.50)                    | 236 (59.00)                        | 1.8 (0.8–4.2)       | 0.160                 |
| No                                            | 13 (3.20)                      | 13 (3.25)                          | -                   | -                     |

OR: Odds ratio; CI: Confidence interval

### Discussion

The results of present study indicate that overall, PWIDIs start injection within the seven years from their first drug use, and it takes about four years from their first injection to be a regular drug injector. The mean age of the first drug experience is about 18 years old, while the mean age of using injecting drug is higher (around 25 years for first injection and 30 years for regular injection). Early transition from first occasion of injection to regular injection was associated with gender, reason, and place of first injection, childhood history of sexual abuse, imprisonmen, and types...
of first drug that has been used.

The result of a systematic review in Iran showed that PWIDs had been using drugs from 4 to 15 years before their first experience of drug injection with the average time of 6 to 7 years and the mean age of 26 years at first injection, which is in line with our results. It seems that PWIDs in Iran experience their first drug injection at older ages compared to other countries in which the age of first injection is 19 to 22 years. Furthermore, the time lag from the first drug use and first injection is relatively high in Iran compared to other countries, and should be regarded as critical time to mobilize prevention efforts and interventions. The most common type of drug at first injection was heroine. Although none of previous studies in Iran reported the initiation of drug injection by stimulants, around 4% of our study participants reported the methamphetamine as the first injecting drug that they used. So, it seems that the pattern of drug injection has been changed. Methamphetamine is the most prevalent drug of injection in Middle East and North Africa (MENA) region, while in other regions, other types of drugs such as cocaine, methamphetamines, and marijuana are more prevalent. This may be partly related to differences in availability of various types of drugs in different regions. For example, in countries such as Iran and most of MENA countries in which non-injecting heroine is more prevalent, it is more likely to be the most frequent injecting drug compared to countries like Canada and the United States of America (USA) in which other types of drugs such as cocaine, methamphetamines, and marijuana are more prevalent.32

Regarding the first type of drug that was used, heroin compared to opium increased the chance of transition into premature regular injection. Other studies confirmed that the risk of transition to injection among heroin users are higher compared to other types of drugs.34 The risk of early transition to regular injection also has been reported to be high among people who used heroin as the first injecting drug compared to other types of drugs.35 It has been suggested that heroine, specially injecting type, has higher degree of dependency compared to other drugs.36

Among the motivators of first injection, having withdrawal symptom, being friend with a drug user, and lower cost of injection compared to other routes of consumption in comparison with curiosity has been associated with decreased likelihood of early regular injection. Although the role of peer drug user, lower cost of injecting drugs, and reaching to higher level of rush transition to drug injection have been established in variety of studies, it seems that someone’s curiosity compared to mentioned factors is more important in premature transition to regular injection. The history of childhood sexual abuse in our study was significantly related to initiation of early regular injection. The relationship between childhood sexual abuse and early initiation of drug injection has been established in various studies. Long-term notorious effects of sexual abuse such as mental disorders (including depression and anxiety) may predispose affected individuals to start injection earlier than those without the history of sexual abuse. Therefore, proper education of families and parents, providing a safer living environment to prevent childhood sexual abuse, and screening and treatment of sexually abused children to reduce adverse mental sequences may be beneficial in prevention of early regular injection.

In our study, the history of imprisonment has been associated with early regular injection. Studies on illicit drug users indicated that having history of incarceration was an important risk factor for initiation of injection in this people. Factors such as low level of access to drugs, high price, and difficulty in use of smoking drugs at prisons were the main causes of injection initiation among incarcerated drug users. Place of first injection was also an important factor that significantly was related to early regular injection. Injection in a friend’s house or ruined buildings compared to one’s own house increased the likelihood of early regular injection.

Our findings are subject to several limitations: The cross-sectional nature of data allowed us associations to be analyzed but not causal inference. The results of present study could not be generalized to all PWIDs. Moreover, a random sample was not drawn, mainly due to lack of access to the sampling frame. Finally, social desirability bias in response to sensitive questions may affect the validity of data.

**Conclusion**

Non-injecting drug users (NIDUs) are at the risk of switching into injecting drug use. Transition into use of injecting drugs and especially

---

http://ahj.kmu.ac.ir, 5 January
premature transition may put them at higher risk of HIV/HCV infection. Therefore, understanding factors related to injection initiation may be beneficial in design and implementation of more targeted programs. New interventions to prevent switching into drug injection among NIDUs are urgently needed and should be designed and evaluated in future researches.

**Conflict of Interests**

The Authors have no conflict of interest.

**References**

1. Small W, Fast D, Krusi A, Wood E, Kerr T. Social influences upon injection initiation among street-involved youth in Vancouver, Canada: A qualitative study. Subst Abuse Treat Prev Policy 2009; 4: 8.
2. Hassannejad R, Kassaian N, Ataei B, Adibi P. High risky behaviors among intravenous drug users in Isfahan, Iran: A study for hepatitis C harm reduction programs. Int J Prev Med 2012; 3(Suppl 1): S73-S78.
3. Amin-Esmaeili M, Rahimi-Movaghar A, Gholamrezaei M, Razaghi EM. Profile of people who inject drugs in Tehran, Iran. Acta Med Iran 2016; 54(12): 793-805.
4. Shahesmaeili A, Haghdoot AA, Soori H. Network location and risk of human immunodeficiency virus transmission among injecting drug users: Results of multiple membership multilevel modeling of social networks. Addict Health 2015; 7(1-2): 1-13.
5. Samimi-Rad K, Nasiri TM, Masoudi-Nejad A, Najafi A, Rahimnia R, Asgari F, et al. Molecular epidemiology of hepatitis C virus among injection drug users in Iran: A slight change in prevalence of HCV genotypes over time. Arch Virol 2012; 157(10): 1959-65.
6. Muntaz GR, Weiss HA, Abu-Raddad LJ. Hepatitis C virus and HIV infections among people who inject drugs in the Middle East and North Africa: A neglected public health burden? J Int AIDS Soc 2015; 18: 20582.
7. Fuller CM, Vlahov D, Arria AM, Ompad DC, Garfein R, Strathdee SA. Factors associated with adolescent initiation of injection drug use. Public Health Rep 2001; 116(Suppl 1): 136-45.
8. Cheng Y, Sherman SG, Srirat N, Vongchak T, Kawichai S, Jittiwutikarn J, et al. Risk factors associated with injection initiation among drug users in Northern Thailand. Harm Reduct J 2006; 3: 10.
9. Moeini B, Mousali A, Hazavei M M, Soltanian A, Barati M, Kafami V. Predicting factors of safe sexual behaviors intention among male addicts covered by substance abuse treatment centers based on theory of planned behavior, in 2013. Pajouhan Scientific Journal 2016; 14(2): 44-52.
10. Karimi M, Ghaheri H, Assari S, Ahmadi K, Moghani Lankarani M, Moghani LR, et al. Drug injection to sites other than arm: A study of Iranian heroin injectors. Front Psychiatry 2014; 5: 23.
11. Assari S, Yarmohammadi Vesal M, Tavakoli M, Sehat M, Jafari F, Narenjiha H, et al. Inconsistent condom use among Iranian male drug injectors. Front Psychiatry 2013; 4: 181.
12. Razzaghi EM, Movaghar AR, Green TC, Khoshnood K. Profiles of risk: A qualitative study of injecting drug users in Tehran, Iran. Harm Reduct J 2006; 3: 12.
13. United Nations Office on Drugs and Crime (UNODC). World drug report [Online]. [cited 2017]; Available from: URL: https://www.unodc.org/wdr2017
14. Bluthenthal RN, Wenger L, Chu D, Lorvick J, Quinn B, Thing JP, et al. Factors associated with being asked to initiate someone into injection drug use. Drug Alcohol Depend 2015; 149: 252-8.
15. DeBeck K, Wood E, Dong H, Dobrer S, Hayashi K, Montaner J, et al. Non-medical prescription opioid use predicts injection initiation among street-involved youth. Int J Drug Policy 2016; 34: 96-100.
16. Arreola S, Bluthenthal RN, Wenger L, Chu D, Thing J, Kral AH. Characteristics of people who initiate injection drug use later in life. Drug Alcohol Depend 2014; 138: 244-50.
17. Miller CL, Strathdee SA, Kerr T, Li K, Wood E. Factors associated with early adolescent initiation into injection drug use: Implications for intervention programs. J Adolesc Health 2006; 38(4): 462-4.
18. Vorobjov S, Des Jalrais DC, Abel-Ollo K, Talu A, Ruutel K, Uusku A. Socio-demographic factors, health risks and harms associated with early initiation of injection among people who inject drugs in Tallinn, Estonia: Evidence from cross-sectional surveys. Int J Drug Policy 2013; 24(2): 150-5.
19. Doherty MC, Garfein RS, Monterroso E, Brown D,  

**Acknowledgements**

We gratefully thank all staff in the drop-in centers in Kerman and Shiraz who contributed in recruiting (Mrs. Farahnaz Farahbakhsh, Dr. Hasanabadi, Mrs. Fariba Rezaee) and data collection/interview (Mr. Esmail Najafi). The information contained in this article was extracted from a master’s thesis in epidemiology by the author, Masoomeh Koozegar, at Kerman University of Medical Sciences.
Vlahov D. Correlates of HIV infection among young adult short-term injection drug users. AIDS 2000; 14(6): 717-26.

20. van Ameijden EJ, van den Hoek JA, Hartgers C, Coutinho RA. Risk factors for the transition from noninjection to injection drug use and accompanying AIDS risk behavior in a cohort of drug users. Am J Epidemiol 1994; 139(12): 1153-63.

21. Mansorian M, Solhi M, Dehdari T, Taghdisi MH, Zamani Alviehe F. Hallucination experience in drug users: A qualitative study. Payesh Health Monit 2014; 13(4): 467-76. [In Persian].

22. Lawshe CH. A quantitative approach to content validity. Pers Psychol 1975; 28(4): 563-75.

23. Haghdooost AA, Guilanipour M, Saberi Zafarghandi MB, Rastegari A, Hajimaghoooodi S, Baneshi MR, et al. Estimation of frequency of misuse of drug and alcohol in Iran in 2012. Tehran, Iran: Sepidbarg Publications; 2013. [In Persian].

24. Shengelia N, Chikovani I, Sulaberidze L. Human immunodeficiency virus prevalence and risk determinants among people who inject drugs in the Republic of Georgia. J Infect Dev Ctries 2017; 11: 772-80.

25. Kielland KB. Mortality, morbidity and treatment uptake related to hepatitis C among people who have injected drugs in Norway [PhD Thesis]. Oslo, Norway: University of Oslo; 2015.

26. Rhodes T, Bivol S, Scutelniciue O, Hunt N, Bernays AH, Uuskula A, et al. Preventing injection drug use: Transitions in self and society. Int J Drug Policy 2011; 22(6): 445-54.

27. Abelson J, Trelaro C, Crawford J, Kippax S, van Beek I, Howard J. Some characteristics of early-onset injection drug users prior to and at the time of their first injection. Addiction 2006; 101(4): 548-55.

28. Harocopos A, Golsamt LA, Kobrak P, Jost JJ, Clatts MC. New injectors and the social context of injection initiation. Int J Drug Policy 2009; 20(4): 317-23.

29. Rahimi-Movaghar A, Amin-Esmaeili M, Shadloo B, Noroozi A, Malekinejad M. Transition to injecting drug use in Iran: A systematic review of qualitative and quantitative evidence. Int J Drug Policy 2015; 26(9): 808-19.

30. Best D, Day E, Cantillano V, Gaston RL, Nambamali A, Sweeting R, et al. Mapping heroin careers: Utilising a standardised history-taking method to assess the speed of escalation of heroin use in a treatment-seeking cohort. Drug Alcohol Rev 2008; 27(2): 165-70.

31. Rahimi-Movaghar A, Amin-Esmaeili M, Aaraj E, Hermez J. Assessment of situation and response to drug use and its harms in the Middle East and North Africa, 2012. Beirut, Lebanon: Middle East and North Africa Harm Reduction Association (MENAHRA); 2013.

32. Roy E, Arruda N, Bruneau J, Jutras-Aswad D. Epidemiology of injection drug use: New trends and prominent issues. Can J Psychiatry 2016; 61(3): 136-44.

33. Al-Tayyib A, Koester S, Langegger S, Raville L. Heroin and methamphetamine injection: An emerging drug use pattern. Subst Use Misuse 2017; 52(8): 1051-8.

34. Bluthenthal R, Chu D, Wenger L, Valente T, Kral A. Does type of drug lead to quicker onset of injection? Drug Alcohol Depend 2015; 156: e21.

35. O'Keefe D, Horyniak D, Dietze P. From initiating injecting drug use to regular injecting: Retrospective survival analysis of injecting progression within a sample of people who inject drugs regularly. Drug Alcohol Depend 2016; 158: 177-80.

36. Gossop M, Griffiths P, Powis B, Strang J. Severity of dependence and route of administration of heroin, cocaine and amphetamines. Br J Addict 1992; 87(11): 1527-36.

37. Yarmohamadi Vasel M, Tavakoli M, Ghanadi F, Farhoudian A, Farhadi MH. Factors associated with the transition from drug abuse to injection of injection drug use. Iran Rehabil J 2015; 13(2): 16-22. [In Persian].

38. Roy E, Haley N, Leclere P, Cedras L, Blais L, Boivin JF. Drug injection among street youths in Montreal: Predictors of initiation. J Urban Health 2003; 80(1): 92-105.

39. Guise A, Horyniak D, Melo J, McNeil R, Werb D. The experience of initiating injection drug use and its social context: A qualitative systematic review and thematic synthesis. Addiction 2017; 112(12): 2098-111.

40. Ompad DC, Ikeda RM, Shah N, Fuller CM, Bailey S, Morse E, et al. Childhood sexual abuse and age at initiation of injection drug use. Am J Public Health 2005; 95(4): 703-9.

41. Hadland SE, Werb D, Kerr T, Fu E, Wang H, Montaner JS, et al. Childhood sexual abuse and risk for initiating injection drug use: A prospective cohort study. Prev Med 2012; 55(5): 500-4.

42. Werb D, Bluthenthal RN, Kolla G, Strike C, Kral AH, Uuskula A, et al. Preventing injection drug use initiation: State of the evidence and opportunities for the future. J Urban Health 2018; 95(1): 91-8.

43. Malekinejad M, Vazirian M, Tavakoli M, Ghanadi F, Farhoudian A, Farhadi MH. Transition to injection amongst opioid users in Iran: Implications for harm reduction. Int J Drug Policy 2012; 23(4): 333-7.

44. Dolan K, Moazen B, Noori A, Rahimzadeh S, Farzadfar F, Hariga F. People who inject drugs in prison: HIV prevalence, transmission and prevention. Int J Drug Policy 2015; 26(Suppl 1): S12-S15.
نگیر الگوی مصرف از اولین تجربه مصرف مواد تا تزریق منظم در بین مصرف‌کنندگان
تزریق مواد در ایران

معصومه کوزه گر۱، دکتر آرمیتا شاه اسماعیلی۲، دکتر مهدی نوروزی۳

چکیده
مقدمه: هدف از انجام مطالعه حاضر، بررسی فاصله زمانی بین اولین تجربه مصرف مواد تا روز اول تزریق منظم و تعیین عوامل مرتبط با تزریق منظم زودرس در بین مصرف‌کنندگان تزریق مواد بود.

روش‌ها: در این پژوهش چند مرکزی، 400 مصرف‌کننده تزریقی مواد با استفاده از روش نمونه‌گیری گلوله، بر روی شاهراه کرمان، شیراز وارد تحقیق شدند. سن اولین تجربه مصرف مواد، سن شروع تزریق منظم مواد و اطلاعات دموگرافیک و رفتاری با استفاده از اسکیوپتیک در روی جمع‌آوری گردید. هدایا با استفاده از اسکیوپتیک، تزریق زودرس به صورت یک‌شانه تزریق منظم مواد به فاصله کمتر از 5 روز از اولین تجربه تزریق تعیین شد. داده‌ها با استفاده از آزمون زیمنسون لجستیک نک متفاوت و جنگ منابع به دست آمده از مورد تحلیل شد.

یافته‌ها: میانگین سنی اولین تجربه مصرف مواد، 21.5/4 ± 32/18 سال و میانگین سنی شروع تزریق منظم، 54/6 ± 87/29 سال بود. دارا بودن سابقه سوء استفاده جنسی در دوران کودکی (نسبت شانس اصلاح شده: 1/3)، سابقه زندانی شدن (نسبت شانس اصلاح شده: 3/4) و با زرخیزی در حالی که زن بود (نسبت شانس اصلاح شده: 2/0) به طور معنی‌داری منجر به کاهش شانس تزریق زودرس شد. دارا بودن سابقه سوء استفاده جنسی در دوران کودکی (نسبت شانس اصلاح شده: 1/3) و سابقه زندانی شدن (نسبت شانس اصلاح شده: 3/4) به طور معنی‌داری منجر به کاهش شانس تزریق زودرس شد. دارا بودن سابقه سوء استفاده جنسی در دوران کودکی (نسبت شانس اصلاح شده: 1/3) و سابقه زندانی شدن (نسبت شانس اصلاح شده: 3/4) به طور معنی‌داری منجر به کاهش شانس تزریق زودرس شد.

نتیجه‌گیری: فاصله زمانی که سه ماه بعد از اولین تجربه مصرف مواد و شروع تزریق منظم مطرح کننده زمان طالبی برای هدف‌گیری مداخلات پیشگیرانه از تزریق مواد می‌باشد نشان‌دهنده عوامل مرتبیت با تزریق زودرس و تعیین گروه‌های آموزشی در طرح‌های و اجرای مداخلات همه جانبه می‌دانند. می‌توان از کاهش شانس تزریق در مصرف‌کنندگان مواد جلوگیری کرد و با آن را به تأخیر انداخت.

واژگان کلیدی: مصرف‌کنندگان تزریقی مواد، زودرس، ایران، عوامل خطر

ارجاع: کوزه گر معصومه، شاه اسماعیلی آرمیتا، نوروزی مهدی. تغییر الگوی مصرف از اولین تجربه مصرف مواد تا تزریق منظم در بین مصرف‌کنندگان تزریقی مواد در ایران. مجله اعتیاد و سلامت 1396؛ 10(1): 40-42.

تاریخ دریافت: 96/8/38
تاریخ پذیرش: 96/8/38

References:
1. Kouraie M, Shahrabi A, Ne оригинал

که واریتور و سایر مواد مصرف شده همراه با تزریق زودرس در بین مصرف‌کنندگان تزریقی مواد در ایران 5 اسفند 1396: 40-42.

ارجاع: کوزه گر معصومه، شاه اسماعیلی آرمیتا، نوروزی مهدی. تغییر الگوی مصرف از اولین تجربه مصرف مواد تا تزریق منظم در بین مصرف‌کنندگان تزریقی مواد در ایران. مجله اعتیاد و سلامت 1396؛ 10(1): 40-42.

تاریخ دریافت: 96/8/38
تاریخ پذیرش: 96/8/38

References:
1. Kouraie M, Shahrabi A, Ne Őlak születése óta. A kutatások, amelyek a fiatalok használata és a használat fokú hosszú idejű, rossz hatások vagy halál utáni státuszokért hivatkoznak a használattól és a használattól függő kohókéktől fogva a halálra. Bár ezek az utalások nem feltétlenül megegyeznek össze, mivel az emberek a használat esetén is különféle hatásokat és tüneteket tapasztalhatnak.

1. Kouraie M, Shahrabi A, Ne Őlak születése óta. A kutatások, amelyek a fiatalok használata és a használat fokú hosszú idejű, rossz hatások vagy halál utáni státuszokért hivatkoznak a használattól és a használattól függő kohókéktől fogva a halálra. Bár ezek az utalások nem feltétlenül megegyeznek össze, mivel az emberek a használat esetén is különféle hatásokat és tüneteket tapasztalhatnak.

1. Kouraie M, Shahrabi A, Ne Őlak születése óta. A kutatások, amelyek a fiatalok használata és a használat fokú hosszú idejű, rossz hatások vagy halál utáni státuszokért hivatkoznak a használattól és a használattól függő kohókéktől fogva a halálra. Bár ezek az utalások nem feltétlenül megegyeznek össze, mivel az emberek a használat esetén is különféle hatásokat és tüneteket tapasztalhatnak.

1. Kouraie M, Shahrabi A, Ne Őlak születése óta. A kutatások, amelyek a fiatalok használata és a használat fokú hosszú idejű, rossz hatások vagy halál utáni státuszokért hivatkoznak a használattól és a használattól függő kohókéktől fogva a halálra. Bár ezek az utalások nem feltétlenül megegyeznek össze, mivel az emberek a használat esetén is különféle hatásokat és tüneteket tapasztalhatnak.